Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 2/20 | 0.41 |
| ▸ | CA1 | P00915 | 2/20 | 0.34 |
| ▸ | CA2 | P00918 | 2/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | PTGES2 | Q9H7Z7 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | SGK1 | O00141 | 5/20 | 0.33 |
| ▸ | SOS1 | Q07889 | 2/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.32 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.32 |
| ▸ | CCR2 | P41597 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29669013 | 1.00 | TRPV4 (0.41) | TRPV4CA1CA2CA9PTGES2 | |
| SCHEMBL29669007 | 1.00 | TRPV4 (0.41) | TRPV4CA1CA2CA9PTGES2 | |
| SCHEMBL30485974 | 0.91 | TRPV4 (0.41) | TRPV4CA1CA2CA9PTGES2 | |
| SCHEMBL1501202 | 0.91 | TRPV4 (0.41) | TRPV4CA1CA2CA9PTGES2 | |
| SCHEMBL1829297 | 0.88 | TRPV4 (0.42) | TRPV4CA1CA2CA9PTGES2 | |
| SCHEMBL29503458 | 0.88 | TRPV4 (0.42) | TRPV4CA1CA2CA9PTGES2 | |
| SCHEMBL3948181 | 0.86 | TRPV4 (0.46) | TRPV4CA1CA2CA9PTGES2 | |
| SCHEMBL320605 | 0.83 | SLC1A3 (0.37) | TRPV4CA1CA2PTGES2CA12 | |
| SCHEMBL29835175 | 0.83 | SLC1A3 (0.37) | TRPV4CA1CA2PTGES2CA12 | |
| SCHEMBL3912870 | 0.82 | TRPV4 (0.46) | TRPV4CA1CA2CA9PTGES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 205 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025024795-A1 | CRYSTALLINE FORMS | NEUROCRINE BIOSCIENCES, INC. (US) | 2025-01-30 | — | — | WO | claimed |
| CN-114591204-B | Preparation and anti-tumor application of anthraquinone sulfonyl spiro derivative | 广西大学 | 2023-04-21 | — | — | CN | claimed |
| CN-114591204-A | Preparation and anti-tumor application of anthraquinone sulfonyl spiro derivative | 广西大学 | 2022-06-07 | — | — | CN | claimed |
| CN-109608369-B | Sulfonyl ester group anthraquinone derivative and preparation method and application thereof | 广西大学 | 2021-04-09 | — | — | CN | claimed |
| WO-2026102309-A1 | SELECTIVE RADIOTRACERS AND METHODS OF USE | LUTROO IMAGING, LLC (US) | 2026-05-15 | — | — | WO | disclosed |
| US-20250326770-A1 | BENZOTRIAZOLE COMPOUND | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2025-10-23 | — | — | US | disclosed |
| US-20250282724-A1 | BENZOTRIAZOLE COMPOUND | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2025-09-11 | — | — | US | disclosed |
| US-12378260-B2 | Benzotriazole compound | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2025-08-05 | — | — | US | disclosed |
| US-20250092064-A1 | BENZOTRIAZOLE COMPOUND | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2025-03-20 | — | — | US | disclosed |
| US-12246008-B2 | 4-amino or 4-alkoxy-substituted aryl sulfonamide compounds with selective activity in voltage-gated sodium channels | MERCK SHARP & DOHME LLC (US) | 2025-03-11 | — | — | US | disclosed |
| EP-3458449-B1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC (CA) | 2025-03-05 | — | — | EP | disclosed |
| EP-4509504-A1 | BENZOTRIAZOLE COMPOUND | Daiichi Sankyo Company, Limited (JP) | 2025-02-19 | — | — | EP | disclosed |
| US-20060040977-A1 | 5-HT7 receptor ligands | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2006-02-23 | — | — | US | disclosed |
| US-20060014759-A1 | Methods for the use of inhibitors of cytosolic phospholipase A2 | WYETH (US) | 2006-01-19 | — | — | US | disclosed |
| US-6797708-B2 | ENZYME INHIBITORS SUCH AS 4-(2-(1-BENZHYDRYL-2-(2-((BENZYL-SULFONYL)AMINO)ETHYL)-5-CHLORO-1H-INDOL-3 -YL)ETHOXY) BENZOIC ACID, USED AS ANALGESICS OR ANTIINFLAMMATORY AGENTS | WYETH | 2004-09-28 | — | — | US | disclosed |
| EP-1451154-A2 | INHIBITORS OF CYTOSOLIC PHOSPHOLIPASE A2 | Wyeth (US) | 2004-09-01 | — | — | EP | disclosed |
| US-20030166649-A1 | Methods for treating arthritic disorders | WYETH | 2003-09-04 | — | — | US | disclosed |
| US-20030149029-A1 | Methods for treating asthmatic conditions | WYETH | 2003-08-07 | — | — | US | disclosed |
| US-20030144282-A1 | Inhibitors of cytosolic phospholipase A2 | WYETH | 2003-07-31 | — | — | US | disclosed |
| WO-2003048122-A2 | INHIBITORS OF CYTOSOLIC PHOSPHOLIPASE A2 | WYETH (US) | 2003-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250092064-A1 | BENZOTRIAZOLE COMPOUND | NFE2L2, BPTF, KEAP1 | TRPV4 2544/4885CA1 4771/4885CA2 3243/4885 |
| US-12378260-B2 | Benzotriazole compound | NFE2L2, BPTF, KEAP1 | TRPV4 2544/4885CA1 4771/4885CA2 3243/4885 |
| US-12246008-B2 | 4-amino or 4-alkoxy-substituted aryl sulfonamide compounds with selective activity in voltage-gated sodium channels | TRPV1, SCN7A, SCN1A | TRPV4 5/4885CA1 2378/4885CA2 496/4885 |
| US-20250326770-A1 | BENZOTRIAZOLE COMPOUND | KEAP1, NFE2L2, TXNRD2 | TRPV4 3953/4885CA1 4804/4885CA2 3963/4885 |
| US-20030166649-A1 | Methods for treating arthritic disorders | PLA2G12A, PLA2G4A, PLA2G4B | TRPV4 658/4885CA1 443/4885CA2 145/4885 |
| US-20060014759-A1 | Methods for the use of inhibitors of cytosolic phospholipase A2 | PLA2G4A, PLA2G4B, PLA2G1B | TRPV4 376/4885CA1 1268/4885CA2 255/4885 |
| US-20060040977-A1 | 5-HT7 receptor ligands | HTR7, HTR1A, HTR5A | TRPV4 503/4885CA1 4722/4885CA2 4859/4885 |
| US-20030149029-A1 | Methods for treating asthmatic conditions | PLA2G4A, PLA2G4B, PLA2G1B | TRPV4 338/4885CA1 1160/4885CA2 88/4885 |
| US-20250282724-A1 | BENZOTRIAZOLE COMPOUND | NFE2L2, BPTF, KEAP1 | TRPV4 2544/4885CA1 4771/4885CA2 3243/4885 |
| US-20030144282-A1 | Inhibitors of cytosolic phospholipase A2 | PLA2G4A, PLA2G4B, PLA2G4C | TRPV4 205/4885CA1 1582/4885CA2 87/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.